Search Results for Drug Advertising

Showing 1 – 14

DTC Drug Ads: New Study Finds Perception of Risks Diluted by Lengthy Side Effects List By Michael Mezher - Published 11 October 2017

A study on direct-to-consumer (DTC) drug advertising published Monday in Nature Human Behavior finds that consumers perceive drugs to be less risky when ads for the drug list all of its side effects compared to when only serious side effects are listed.

Categories: News, US, FDA, Advertising and Promotion, Drugs

Tags: Direct-to-Consumer, Drug Advertising, Side Effects, Risk

PhRMA Criticizes FDA's 'Unnecessary' Research on Drug Advertising and Promotion By Zachary Brennan - Published 16 August 2017

The pharmaceutical industry lobbying group known as the Pharmaceutical Research and Manufacturers of America (PhRMA) is harshly criticizing the US Food and Drug Administration's (FDA) research focused on prescription drug advertising and promotion and calling for a clearer vision on how this research protects public health.

Categories: News, US, FDA, Advertising and Promotion, Biologics and biotechnology, Drugs, Government affairs, Quality, Regulatory strategy

Tags: PhRMA, drug advertising and promotion, FDA research

FDA Officials Study Alternative Approach to Presenting Risk Info in TV Drug Ads By Michael Mezher - Published 07 August 2017

A recent study by US Food and Drug Administration (FDA) officials and research firm RTI International suggests that an alternative approach to presenting limited risk information in direct-to-consumer (DTC) TV drug advertising may improve consumers' ability to recall those risks.

Categories: News, US, FDA, Advertising and Promotion, Drugs

Tags: Direct-to-Consumer, DTC, Drug Advertising, Risk, Fair Balance

Australia’s TGA to Take Over Regulation of Therapeutic Goods Advertising By Zachary Brennan - Published 07 July 2017

Beginning 1 July 2018, Australia’s Therapeutic Goods Administration (TGA) will be responsible for receiving and considering all complaints about drug and medical device advertisements directed at the public under what it calls "a simplified complaints system."

Categories: News, Oceania, TGA, Advertising and Promotion, Biologics and biotechnology, Drugs, Medical Devices

Tags: TGA, drug advertising Australia

Asia Regulatory Roundup: Australia Considers Some DTC Drug Ads (4 April 2017) By Nick Paul Taylor - Published 04 April 2017

Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia.

Categories: News, Asia, CDSCO, TGA, Biologics and biotechnology, Drugs, Medical Devices, Research and development

Tags: drug advertising, oxytocin, DRAP

Asia Regulatory Roundup: Vietnam Drug Agency Adds Aurobindo, Other Indian Drugmakers to Blacklist (15 November 2016) By Nick Paul Taylor - Published 15 November 2016

Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia.

Categories: News, Asia, CDSCO, CFDA, MHLW, TGA, Biologics and biotechnology, Drugs, Labeling, Medical Devices, Regulatory intelligence, Regulatory strategy

Tags: drug advertising, social media and pharmaceuticals, Aurobindo Pharma

Case Study: Regulatory Advertising and Promotion From a Fellow’s Perspective By John Riehl - Published 16 October 2015

This article discusses three components of Purdue University’s Regulatory Pharmaceutical Fellowship from a current fellow’s perspective followed by a candid interview.

Categories: Features, US, FDA, Advertising and Promotion, Business Skills, Drugs

Tags: drug advertising and promotion, FDA, Purdue University, Johnson & Johnson, Eli Lilly, regulatory pharmaceutical fellowship

Prescription Drug Advertising Versus Non-Advertising Promotion in China: Contrasting Regulation By Denise Sanchez - Published 13 October 2015

This article discusses the contrasts between regulatory oversight of prescription drug advertising and non-advertising promotion in China.

Categories: Features, China, CFDA, Advertising and Promotion, Drugs, Due Diligence, Ethics

Tags: CFDA, China FDA, drug advertising, non-advertising promotion

Celebrity Endorsements—Lights, Camera, Enforcement Action? By Georgina Lee, PharmD - Published 23 September 2015

This article discusses the use of celebrity endorsements to promote a disease state or a pharmaceutical drug.  

Categories: Features, US, FDA, Advertising and Promotion, Drugs, Due Diligence, Ethics, Regulatory intelligence, Regulatory strategy

Tags: Kim Kardashian, OPDP, warning letter, drug advertising, DTCA, Samuel L. Jackson

Do Price Comparisons Affect How Safe Patients Think a Drug is? FDA Plans to Find Out By Alexander Gaffney, RAC - Published 03 April 2015

The US Food and Drug Administration (FDA) plans to study whether including pricing information on the label of a pharmaceutical product affects how consumers view the safety and efficacy of drug products, especially when comparisons are made between two drugs.

Categories: News, US, CDER, Advertising and Promotion, Biologics and biotechnology, Drugs, Labeling

Tags: Drug Advertising, Pharmaceutical Advertising, OPDP, Office of Prescription Drug Promotion, Price Comparisons in Drug Advertising

FDA Calls for Changes to Drug Advertising in Hopes of Increasing Patient Understanding By Alexander Gaffney, RAC - Published 06 February 2015

The pharmaceutical advertising you see in magazines and newspapers will soon include less information in the hopes of better conveying what the actual risk of the drug is, the US Food and Drug Administration (FDA) announced today.

Categories: News, US, CDER, Advertising and Promotion, Biologics and biotechnology, Drugs, Labeling

Tags: DTC Advertising, FDA Regulation of Advertising, Pharmaceutical Advertising, Drug Advertising, Guidance, Draft Guidance, OPDP

FDA Drug Advertising Study Tracker By Alexander Gaffney, RAC - Published 12 January 2015

The US Food and Drug Administration (FDA) frequently studies consumer behavior, particularly as it relates to how members of the public (and medical professionals) understand pharmaceutical advertising. Our FDA Drug Advertising Study Tracker keeps tabs on these studies and explains what they're trying to accomplish in plain terms.

Categories: News, US, CDER, Advertising and Promotion, Biologics and biotechnology, Drugs, Labeling

Tags: Direct-to-Consumer Drug Advertising, DTC Drug Advertising, FDA Regulation of Drug Advertising, FDA Studies

Does Your Spouse Affect How you Perceive Drug Safety? An FDA Study Aims to Find out By Alexander Gaffney, RAC - Published 13 November 2014

The US Food and Drug Administration (FDA) has announced another proposed study of consumers who watch drug advertising on TV—the second this week—this time trying to assess how spouses influence how consumers understand a drug's benefits and risks.

Categories: News, US, CDER, Advertising and Promotion, Drugs

Tags: DTC Advertising, OPDP, Study, Drug Advertising, Spouse

Do Distractions in Drug Ads Put Consumers at Risk? FDA Study to Find out By Alexander Gaffney, RAC - Published 12 September 2014

The US Food and Drug Administration (FDA) has received approval to go forward with a proposed study to study the effects of "distractions" in direct-to-consumer drug advertising, which it hypothesizes may reduce consumers' ability to remember risk information about a product.

Categories: News, US, CDER, Biologics and biotechnology, Drugs, Labeling

Tags: DTC Advertising, Direct-to-Consumer Drug Advertising, Pharmaceutical Advertising, Distractions in Drug Advertisements